摘要
目的探讨基于QQ群健康教育在抗病毒治疗艾滋病患者的应用效果。方法将200例抗病毒治疗艾滋病患者按随机数字表法分为对照组和观察组各100例,对照组给予常规护理,观察组在对照组基础上采用QQ群方式进行健康教育。观察比较2组患者服药依从率、CD4+T淋巴细胞计数、HIV-RNA载量<20拷贝/m L的患者例数、机会性感染的发生率和死亡率。结果干预12个月末,观察组服药依从率高于对照组(P<0.01);观察组CD4+T淋巴细胞计数高于对照组,观察组患者HIV-RNA载量<20拷贝/m L的患者例数多于对照组,机会感染发生率低于对照组,差异均有统计学意义(P<0.05);2组患者死亡率比较差异无统计学意义(P>0.05)。结论基于QQ群健康教育可提高艾滋病患者抗病毒治疗服药依从性,能有效提高其体内CD4+T淋巴细胞和降低HIV-RNA载量水平,减少机会性感染发生。
Objective To explore the effect of health education based on QQ group platform in patients with HIV/AIDS antiviral treatment. Methods Two hundred patients with HIV/AIDS antiviral treatment were divided into control group and observation group with 100 cases in each group. Conventional nursing care was conducted in control group and health education based on QQ platform in observation group. Patients （ medication compliance, CD4T lymphocyte count, cases of patients with HIV RNA loads〈20 copies/mL, the incidence of opportunistic infection and mortality in 2 groups were compared. Results There was better medication compliance in observation group than that in control group at the end of 12-month intervention （P〈0.01）; there were higher CD4 ＇ T lymphocyte count, lower incidence of opportunistic infection and more cases with HIV RNA loads〈20 copies/mL in observation group than those in control group and the difference was statistically significant （P〈0.05） but no statistical significance was found in mortality in 2 groups （P〉0.05）. Conclusion QQ platform-based health education can improve the medication compliance of antiviral treatment in patients with HIV/AIDS, effectively improve CD4^＋ T cell count and reduce HIV -RNA level and the incidence of opportunistic infections.
作者
宁艳春
龚世江
韦秀柏
戚茂超
唐月璐
蒙志好
NING Yan-chun a GONG Shi-jiang a WEI Xiu-bai a QI Mao-chao b TANG Yue-lu c MENG Zhi-hao a(Longtan Hospital of Guangxi Zhuang Autonomous Region, a.Care Clini b. Dept, of Nutriolog c. Dept, of Nursing Administration, Liuzhou 545005,Chin)
出处
《护理学报》
2017年第11期59-62,共4页
Journal of Nursing（China）
基金
广西壮族自治区卫生厅自筹经费科研课题(Z2013279)
关键词
QQ群
艾滋病
抗病毒治疗
依从性
QQ group
HIV/AIDS
antiviral treatment
compliance
